Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

FoxO3a confers cetuximab resistance in RAS wild-type metastatic colorectal cancer through c-Myc.

Oncotarget - 6 Dec 2016

Yu Yiyi, Guo Mengzhou, Wei Ye, Yu Shan, Li Hong, Wang Yan, Xu Xiaojing, Cui Yuehong, Tian Jiawen, Liang Li, Peng Ke, Liu Tianshu

Abstract excerpt

Resistance to epidermal growth factor receptor (EGFR) targeted monoclonal antibody therapy represents a clinical challenge in patients suffered from RAS wild-type (WT) metastatic colorectal cancer (mCRC). However, the molecular mechanisms and key factors conferring this resistance are largely unknown. Forkhead transcription factors of the O class 3a (FoxO3a), an important regulator of cell survival, has been...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Immunological
Share to Caco-2 Cells

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cetuximab

Share to Forkhead Box Protein O3

Share to HT29 Cells

Share to Mice, Nude

Share to Proto-Oncogene Proteins c-myc

Share to Tumor Burden

Source

Open in PubMed Open full text

Identifiers

PMID: 27825133
DOI: 10.18632/oncotarget.13105
PMCID: PMC5348362

Genes

ACO2
BRAF
EGFR
LARS2
MRPL12

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

FoxO3a confers cetuximab resistance in RAS wild-type metastatic colorectal cancer through c-Myc.PMID 27825133Read ↗

Qualitative Ras pathway signature for cetuximab therapy reveals resistant mechanism in colorectal cancer.Semantic proximity Read ↗

MOGAT3-mediated DAG accumulation drives acquired resistance to anti-BRAF/anti-EGFR therapy in BRAFV600E-mutant metastatic colorectal cancerSemantic proximity Read ↗

Role and regulation of the forkhead transcription factors FOXO3a and FOXM1 in carcinogenesis and drug resistanceSemantic proximity Read ↗

LncRNA BLACAT1/miR-519d-3p/CREB1 Axis Mediates Proliferation, Apoptosis, Migration, Invasion, and Drug-Resistance in Colorectal Cancer ProgressionSemantic proximity Read ↗

Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies.Semantic proximity Read ↗

Predictive and Therapeutic Implications of a Novel PLCγ1/SHP2-Driven Mechanism of Cetuximab Resistance in Metastatic Colorectal Cancer.Semantic proximity Read ↗

Negative correlation between acetyl-CoA acyltransferase 2 and cetuximab resistance in colorectal cancer.Semantic proximity Read ↗

The Emerging Role of NRAS Mutations in Colorectal Cancer Patients Selected for Anti-EGFR Therapies.Semantic proximity Read ↗

The FOXO3-FOXM1 axis: A key cancer drug target and a modulator of cancer drug resistanceSemantic proximity Read ↗

IGF2BP3 promotes progression of colorectal cancer and mediates cetuximab resistance by stabilizing EGFR mRNA in an m6A-dependent mechanismSemantic proximity Read ↗

Linking FOXO3, NCOA3, and TCF7L2 to Ras pathway phenotypes through a genome-wide forward genetic screen in human colorectal cancer cells.Semantic proximity Read ↗

Mechanisms of resistance to anti-EGFR therapy in colorectal cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.